Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study

Khalkhali, Mohammadrasoul; Golshahi, Mahboobeh; Hasandokht, Tolou; Kafie, Moosa; Zare, Roghaye

Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study

Document Type : Original Article

Authors

¹ Department of Psychiatry, Shafa Psychiatry Hospital, Guilan University of Medical Sciences, Rasht, Iran

² Department of Psychology, University of Guilan, Rasht, Iran

³ Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Methamphetamine-induced psychotic disorder (MIP) cannot be easily differentiated from other psychotic disorders. Some studies have reported that patients with MIP and schizophrenia have differences in their cognitive functioning. We hypothesized that their performance would be different on neuropsychological tests which assess executive functions and visual memory. Materials and Methods: In a cross-sectional study, 30 patients with MIP, 31 patients with schizophrenia, and 31 healthy controls were assessed by Rey–Osterrieth complex figure (ROCF) test and visual search and attention test (VSAT). One-way analysis of variance was performed to compare the mean scores of tests. Tukey's HSD test was used for post hoc analysis. Results: Three groups had significant differences according to ROCF test (F = 15.76, P < 0.0001), VSAT (F = 39.78, P < 0.0001), left VSAT (F = 37.96, P < 0.0001), right VSAT (F = 40.40, P < 0.0001), and the time of the test administration (F = 3.26, P = 0.04). The post hoc analysis showed that the mean score of ROCF test and VSAT (total, right, and left) was significantly higher in the control group than in the other two groups. The time of administering the test in the control group was significantly shorter than in the MIP group (P < 0.03) and nonsignificantly shorter than in the schizophrenia group (P = 0.54). The mean score of right side VSAT was significantly higher in the MIP group than in the schizophrenia group. Conclusion: ROCF could not differentiate MIP from schizophrenia. The better performance of patients with MIP on right side VSAT that is reported in this and in the previous study needs to be reevaluated in more controlled studies.

Keywords

References

1.	Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iran Med 2002;5:184-90.
2.	Mehrpour O. Methamphetamin abuse a new concern in Iran. Daru 2012;20:73.
3.	Shariatirad S, Maarefvand M, Ekhtiari H. Emergence of a methamphetamine crisis in Iran. Drug Alcohol Rev 2013;32:223-4.
4.	Lashkaripour K, Torbati E. Methamphetamine dependency. Int J High Risk Behav Addcict 2012;1:7-8.
5.	Zarrabi H, Khalkhali M, Hamidi A, Ahmadi R, Zavarmousavi M. Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients. BMC Psychiatry 2016;16:44.
6.	Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J 2006;8:E413-8.
7.	Kita T, Miyazaki I, Asanuma M, Takeshima M, Wagner GC. Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity. Int Rev Neurobiol 2009;88:43-64.
8.	Kita T, Takeshima M, Wagner GC, Hozumi H, Miyazaki I, Asanuma M. New perspectives on the mechanism of methamphetamine-induced neurotoxicity. Nihon Shinkei Seishin Yakurigaku Zasshi 2008;28:49-61.
9.	Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, et al. Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 2013;129:167-79.
10.	McKetin R, Hickey K, Devlin K, Lawrence K. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev 2010;29:358-63.
11.	Camacho A, Akiskal HS. Proposal for a bipolar-stimulant spectrum: Temperament, diagnostic validation and therapeutic outcomes with mood stabilizers. J Affect Disord 2005;85:217-30.
12.	Mahoney JJ 3^rd, De La Garza R 2^nd, Jackson BJ, Verrico CD, Ho A, Iqbal T, et al. The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Res 2014;219:367-71.
13.	Vosburgh HW, Mansergh G, Sullivan PS, Purcell DW. A review of the literature on event-level substance use and sexual risk behavior among men who have sex with men. AIDS Behav 2012;16:1394-410.
14.	Herbeck DM, Brecht ML. Substance use and mental health characteristics associated with cognitive functioning among adults who use methamphetamine. J Addict Dis 2013;32:11-25.
15.	McKetin R, Lubman DI, Najman JM, Dawe S, Butterworth P, Baker AL. Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study. Addiction 2014;109:798-806.
16.	Khalkhali SM, Najafi K, Ahmadi R, Yousefnezhad A, Hamidi A, Ellahi M, et al. Domestic violence in methamphetamine psychotic users, psychiatric inpatients, and healthy people: A comparative study. Iran J Med Sci 2016;41:486-93.
17.	Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg EM, et al. Amphetamine-induced psychosis – A separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012;12:221.
18.	Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Neurol Clin 2011;29:641-55.
19.	Kiyatkin EA. The hidden side of drug action: Brain temperature changes induced by neuroactive drugs. Psychopharmacology (Berl) 2013;225:765-80.
20.	Cadet JL, Krasnova IN. Molecular bases of methamphetamine-induced neurodegeneration. Int Rev Neurobiol 2009;88:101-19.
21.	Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. J Neuropsychiatry Clin Neurosci 2003;15:317-25.
22.	Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol 2012;7:113-39.
23.	Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al. Methamphetamine use and schizophrenia: A population-based cohort study in California. Am J Psychiatry 2012;169:389-96.
24.	Srisurapanont M, Arunpongpaisal S, Wada K, Marsden J, Ali R, Kongsakon R, et al. Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:959-64.
25.	Orellana G, Slachevsky A. Executive functioning in schizophrenia. Front Psychiatry 2013;4:35.
26.	Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: A critical review and meta-analysis. Neuropsychol Rev 2007;17:275-97.
27.	Hart CL, Marvin CB, Silver R, Smith EE. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology 2012;37:586-608.
28.	van Holst RJ, Schilt T. Drug-related decrease in neuropsychological functions of abstinent drug users. Curr Drug Abuse Rev 2011;4:42-56.
29.	Nagai T, Yamada K. Molecular mechanism for methamphetamine-induced memory impairment. Nihon Arukoru Yakubutsu Igakkai Zasshi 2010;45:81-91.
30.	North A, Swant J, Salvatore MF, Gamble-George J, Prins P, Butler B, et al. Chronic methamphetamine exposure produces a delayed, long-lasting memory deficit. Synapse 2013;67:245-57.
31.	Chung A, Lyoo IK, Kim SJ, Hwang J, Bae SC, Sung YH, et al. Decreased frontal white-matter integrity in abstinent methamphetamine abusers. Int J Neuropsychopharmacol 2007;10:765-75.
32.	Weber E, Blackstone K, Iudicello JE, Morgan EE, Grant I, Moore DJ, et al. Neurocognitive deficits are associated with unemployment in chronic methamphetamine users. Drug Alcohol Depend 2012;125:146-53.
33.	Chen CK, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC, et al. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug Alcohol Depend 2015;148:158-64.
34.	Diamond A. Executive functions. Annu Rev Psychol 2013;64:135-68.
35.	Trenerry MR, Croosson B, Deboe J, Leber WR. Visual Search Attention Test. Odessa, Florida: Psychological Assessment Resources, Inc.; 1990.
36.	Filoteo JV, Williams BJ, Rilling LM, Roberts JV. Performance of Parkinson's disease patients on the visual search and attention test: Impairment in single-feature but not dual-feature visual search. Arch Clin Neuropsychol 1997;12:621-34.
37.	Jacobs E, Fujii D, Schiffman J, Bello I. An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. Cogn Behav Neurol 2008;21:98-103.
38.	Ezzatpanah Z, Shariat SV, Tehrani-Doost M. Cognitive functions in methamphetamine induced psychosis compared to schizophrenia and normal subjects. Iran J Psychiatry 2014;9:152-7.
39.	Bramness JG, Rognli EB. Psychosis induced by amphetamines. Curr Opin Psychiatry 2016;29:236-41.
40.	Salo R, Ursu S, Buonocore MH, Leamon MH, Carter C. Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: A functional magnetic resonance imaging study. Biol Psychiatry 2009;65:706-9.
41.	Morgan EE, Woods SP, Poquette AJ, Vigil O, Heaton RK, Grant I. Visual memory in methamphetamine-dependent individuals: Deficient strategic control of encoding and retrieval. Aust N Z J Psychiatry 2012;46:141-52.
42.	Semkovska M, Bédard MA, Godbout L, Limoge F, Stip E. Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res 2004;69:289-300.
43.	Mitrushina M, Boone K, Razani J, D'Elia L. Handbook of Normative Data for Neuropsychological Assessment. 2^nd ed. USA:Oxford University Press; 2005. p. 241-53.
44.	Shin MS, Park SY, Park SR, Seol SH, Kwon JS. Clinical and empirical applications of the Rey-Osterrieth Complex Figure Test. Nat Protoc 2006;1:892-9.
45.	Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2^nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
46.	Collins A, Koechlin E. Reasoning, learning, and creativity: Frontal lobe function and human decision-making. PLoS Biol 2012;10:e1001293.
47.	Lunt L, Bramham J, Morris RG, Bullock PR, Selway RP, Xenitidis K, et al. Prefrontal cortex dysfunction and ‘jumping to conclusions’: Bias or deficit? J Neuropsychol 2012;6:65-78.
48.	Rossi AF, Pessoa L, Desimone R, Ungerleider LG. The prefrontal cortex and the executive control of attention. Exp Brain Res 2009;192:489-97.
49.	Gazzaley A, Nobre AC. Top-down modulation: Bridging selective attention and working memory. Trends Cogn Sci 2012;16:129-35.
50.	Nobre AC, Stokes MG. Attention and short-term memory: Crossroads. Neuropsychologia 2011;49:1391-2.
51.	Elahipanah A, Christensen BK, Reingold EM. Visual selective attention among persons with schizophrenia: The distractor ratio effect. Schizophr Res 2008;105:61-7.
52.	Lu PH, Boone KB, Cozolino L, Mitchell C. Effectiveness of the Rey-Osterrieth Complex Figure Test and the Meyers and Meyers recognition trial in the detection of suspect effort. Clin Neuropsychol 2003;17:426-40.
53.	Göder R, Boigs M, Braun S, Friege L, Fritzer G, Aldenhoff JB, et al. Impairment of visuospatial memory is associated with decreased slow wave sleep in schizophrenia. J Psychiatr Res 2004;38:591-9.
54.	Behrmann M, Geng JJ, Shomstein S. Parietal cortex and attention. Curr Opin Neurobiol 2004;14:212-7.
55.	Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci 2014;97:37-44.
56.	Bernheim A, See RE, Reichel CM. Chronic methamphetamine self-administration disrupts cortical control of cognition. Neurosci Biobehav Rev 2016;69:36-48.
57.	Huang M, Huang Y, Yu L, Hu J, Chen J, Jin P, et al. Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. BMC Psychiatry 2016;16:344.
58.	Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006;86:138-46.

Advanced Biomedical Research